Safety, Tolerability and Pharmacokinetic/Pharmacodynamic Characteristics of LC350189 After Oral Administration in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 10 Jun 2013
At a glance
- Drugs LC 350189 (Primary) ; Febuxostat
- Indications Gout
- Focus Adverse reactions
- Sponsors LG Life Sciences
- 01 Jan 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Apr 2012 Planned number of patients changed from 72 to 102 as reported by ClinicalTrials.gov.
- 27 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.